We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.
- Authors
Brat, Daniel J.; Aldape, Kenneth; Colman, Howard; Figrarella-Branger, Dominique; Fuller, Gregory N.; Giannini, Caterina; Holland, Eric C.; Jenkins, Robert B.; Kleinschmidt-DeMasters, Bette; Komori, Takashi; Kros, Johan M.; Louis, David N.; McLean, Catriona; Perry, Arie; Reifenberger, Guido; Sarkar, Chitra; Stupp, Roger; van den Bent, Martin J.; von Deimling, Andreas; Weller, Michael
- Abstract
Both high levels of copy number variations (CNV) and somatic mutations have been associated with higher histologic grade among IDH-mutant astrocytomas and with shorter overall survival in patients with WHO grade II or III IDH-mutant astrocytomas [[1], [9], [28]]. IDH-mutant astrocytomas that lack significant mitotic activity, histologic anaplasia, microvascular proliferation, necrosis and I CDKN2A/B i homozygous deletion are referred to as Astrocytoma, IDH-mutant, grade 2. An IDH-mutant astrocytoma that contains elevated mitotic activity and histologic anaplasia, yet lacks microvascular proliferation, necrosis and I CDKN2A/B i homozygous deletion, currently fits into the designation of Astrocytoma, IDH-mutant, grade 3.
- Subjects
CENTRAL nervous system tumors; NERVOUS system tumors; GENE amplification; ASTROCYTOMAS
- Publication
Acta Neuropathologica, 2020, Vol 139, Issue 3, p603
- ISSN
0001-6322
- Publication type
Article
- DOI
10.1007/s00401-020-02127-9